The national collection of proprietary Chinese medicines has begun, and the Chinese medicine tablet industry has ushered in development opportunities

In September 2021, the General Office of the State Council issued the "14th Five-Year Plan for National Medical Security", which proposes that by 2025, the expected target of the number of varieties of drugs purchased in various provinces (autonomous regions and municipalities directly under the Central Government) should be greater than 500, and the amount of drugs collected by public medical institutions through the provincial centralized procurement platform accounts for 90%
of the total amount of drugs purchased (excluding traditional Chinese medicine tablets).
。 In order to implement the spirit of the relevant documents of the Party Central Committee and the State Council, as early as 2020, Qinghai, Jinhua, Puyang and other places have carried out preliminary exploration of some proprietary Chinese medicine varieties; In 2021, Hubei, Guangdong, Shandong, Beijing and other places have also successively promoted the local collection and collection of proprietary Chinese medicines in the form of provincial or inter-provincial alliances
.
So under the leadership of the national wave of collective procurement, what kind of impact will pharmaceutical companies be affected? And how to calmly deal with the impact of collection? Hangzhou Tanggu Traditional Chinese Medicine Pharmaceutical Research Team carefully studied the relevant policies and analyzed them as follows
.

Medical Insurance Bureau: The collection of proprietary Chinese medicines should be both good and expensive

In order to solve the problems of decoupling of quantity and price in the drug purchase and sales chain, irregular competition, and sales with gold, this year, following the collection of proprietary Chinese medicines such as Qing Kailing of the Guangdong Alliance and the special collection of proprietary Chinese medicines in Shandong Province, led by Hubei Province, and jointly established by 29 provinces (autonomous regions and municipalities directly under the Central Government) and the Xinjiang Production and Construction Corps, the Chinese Proprietary Medicines Alliance has also officially opened the second round of proprietary Chinese medicine collection
。 According to the official documents released by the Procurement Office of the Interprovincial Alliance of Chinese Proprietary Medicines in Hubei Province last year, the comprehensive score of the reporting enterprise is composed of two parts: the price competition score and the technical evaluation score, and the final shortlisted enterprises are determined by comprehensively considering the price reduction, the recognition of medical institutions, the ranking of enterprises
, the supply capacity, the ability to innovate, the price of medicine, the credit evaluation level of the recruitment and procurement, and the quality and safety of the drugs 。 In response to the concerns of industry insiders that the price of individual proprietary Chinese medicines has dropped too much, corporate profits have been greatly compressed, which is not conducive to the long-term development of proprietary Chinese medicines, the official statement of the National Medical Security Research Institute said that "the goal of drug collection reform is not simply to reduce prices, let alone the greater the reduction, the better, the lower the price, the better.
"
The results of the selection also show that the collection of proprietary Chinese medicines is not "only low price" is taken, but while removing the "puffiness" of profits, taking into account the quality of
drugs.
In short, the centralized procurement with quantity aims to wring out the unreasonable "water" in the process of drug supply and circulation, help enterprises establish reasonable income expectations, and guide enterprises to shift more energy from publicity and marketing to improving production quality and drug efficacy while stabilizing sales, and then promote the high-quality development of the proprietary Chinese medicine industry, which is a big project
that benefits all parties and benefits the country.

Shrinking profits, how should enterprises calmly cope

According to the results of the first batch of collection and selection of the Hubei Interprovincial Alliance of Proprietary Chinese Medicines, the average price of the selected products fell by more than 40%, and the decline of individual varieties was as high as 80%.

Even if the company did not sell at a loss, the profits obtained did suffer a sharp reduction
compared to before the collection.
While conscientiously studying, fully understanding and strictly implementing the relevant national policies, enterprises may also change the unipolar development thinking pattern, integrate diversified business coordination, use the Taoist arts and use the same as the same to explore the win-win points and balance points of the interests of enterprises and the public, which is a long-term policy and a solid move
in line with China's national conditions.
Reinventing the business model will highlight the need to some extent
.
Since the Eighteenth National Congress of the Communist Party of China, China's traditional Chinese medicine industry has ushered in new opportunities for historical development, and the policy system of traditional Chinese medicine has become more and more comprehensive
.
For example, the "Opinions on Promoting the Inheritance and Innovative Development of Traditional Chinese Medicine" issued by the CPC Central Committee and the State Council clearly stated that it is necessary to build a grass-roots TCM service position and support TCM hospitals to take the lead in forming a medical consortium
.
Traditional Chinese medicine hospitals at all levels should strengthen the guidance
of grass-roots traditional Chinese medicine services.
The "14th Five-Year Plan" of Chinese Medicine Development Plan points out that it is necessary to improve the level of informatization of traditional Chinese medicine and optimize the medical service model of
traditional Chinese medicine.
Promote the construction of smart Chinese medicine hospitals with "trinity" of smart medical treatment, smart services and
smart management.
To put it simply, while strengthening cost control, improving production capacity efficiency, and promoting the innovation and upgrading of R&D and upgrading of proprietary Chinese medicines, pharmaceutical companies can take traditional Chinese medicine tablets as the starting point, medical associations and medical communities as the support, and through diversified investment, cooperate with hospital customers to build and share Chinese pharmacies, smart Chinese pharmacies, medical community remote clinics, automated decoction centers, regional Chinese medicine preparation centers, Chinese medicine practitioners continuing education platform, Chinese medicine treatment of pre-existing disease health management platform, Chinese medicine supply chain whole process traceability platform, Chinese medicine dialectical treatment intelligent auxiliary diagnosis and treatment platform, etc.
Disperse non-systemic risks of enterprises, improve the service capacity of traditional Chinese medicine, expand the supply of high-quality traditional Chinese medicine services, tighten the cooperation bond between hospital customers, promote market expansion, and ultimately achieve a win-win situation
for doctors, patients, governments and enterprises.

The "big incision" of traditional Chinese medicine tablets may usher in a golden period of development

Chinese herbal medicines, Chinese medicine tablets and proprietary Chinese medicines are the three pillars
of China's Chinese medicine industry.
Some industry analysts believe that due to the particularity of the field of Chinese herbal medicines and Chinese medicine tablets, the possibility of national collection in the future is minimal
.
For Chinese medicine tablets, it can not only be used as raw materials for proprietary Chinese medicine, but also can be directly used in TCM clinics, with a good mass base and a wide range of application scenarios; At present, Chinese medicine tablets are not limited by the proportion of drugs, and provinces still allow medical institutions to retain the Shunjia bonus, which has a high profit margin
.
Based on this, many domestic pharmaceutical giants have spent money to "re-inject" the layout of the traditional Chinese medicine medical association, aiming to strengthen the market of the traditional Chinese medicine tablet industry and revitalize the county's medical and health resources
.
Under the traditional model, grass-roots TCM medical institutions have nine major problems
, such as lack of information and data sharing, lack of physician resources, insufficient pharmacist ability, irregular decoction service, high procurement cost of drinking tablets, long storage cycle of drinking tablets, no traceability of drinking tablet information, opaque decoction process, and incomplete varieties of drinking tablets.
Relying on the medical community of the medical federation, it is conducive to promoting the expansion and sinking of high-quality medical resources and a balanced layout, effectively solving the nine major problems in the operation of grass-roots medical institutions, so that grass-roots people can enjoy high-quality medical services
at their doorstep.
The medical community shared Chinese pharmacy platform is a comprehensive Chinese medicine pharmacy service platform integrating all aspects of drug collection, maintenance, prescription review, deployment, decoction, distribution, and drug ordering, and its core functions include regional prescription circulation and prescription review, shared Chinese pharmacy management and Chinese medicine service intelligent management
.
Realize the unified summary of prescriptions, the unified management of pharmaceutical affairs, the unified distribution of decoction, and the unified service of
patients.

With the improvement of the development policy of traditional Chinese medicine and the continuous strengthening of regulatory measures, the traditional Chinese medicine industry may face great changes in the times, but there will inevitably be more strategic new opportunities in the turbulent changes, and it is bound to lead enterprises to cultivate opportunities in the crisis, open up new situations in the changing situation, broaden the innovative business, and open up a prosperous scene
.